Skip to content

Joshua Lipson

6 papers in the library · 115 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Baseline Mood and “Relational Triad” Predict Acute Qualities of Psychedelic Experience

Behavioral Sciences February 23, 2026 Joshua Lipson, Hannes Kettner, Robin Carhart-Harris et al.

BACKGROUND: The quality and valence of psychedelic experiences are influenced by a range of psychological and contextual factors. This study examines baseline mood and the "relational triad"-comprising social connectedness, mindfulness, and spirituality-as potential predictors of the quality of naturalistic psychedelic experiences. METHODS: Data were drawn from the Predicting Responses to...

Self, Other, and Higher Power: A “Relational Triad” Moderates Associations Between Mystical Experience and Mental Health

The international journal for the psychology of religion October 1, 2024 Joshua Lipson, Thomas Ford, Miles Beattie et al.

ABSTRACT The present study aimed to characterize the relationship between mystical experience and psychopathology measures in a general-population sample of 763 U.S. adults. The participants were assessed across various domains including psychopathology, spirituality, personality, and life experience. The analysis revealed three distinct profiles among individuals: Transcendent Wellness,...

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample

Scientific Reports February 11, 2023 Grant Jones, Joshua Lipson, Erica Wang 2 citations

Abstract Impairment in social functioning is a common source of morbidity across many mental health disorders, yet there is a dearth of effective and easily implemented interventions to support social functioning. MDMA/ecstasy and classic psychedelics (psilocybin, LSD, peyote, mescaline) represent two potential treatments for impairments in social functioning, as evidence suggests these...

Associations between classic psychedelics and nicotine dependence in a nationally representative sample

Scientific Reports June 22, 2022 Grant Jones, Joshua Lipson, Matthew K. Nock 31 citations

Abstract Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we...

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

Frontiers in Psychology May 23, 2022 Tomas Frymann, Sophie Whitney, David B. Yaden et al. 26 citations

In this study, we describe the development and initial validation of two psychometric scales for measuring psychedelic integration. Psychedelic integration refers to the post-acute period of time following psychedelic drug administration. We created the Integration Engagement Scale (IES) to capture positive behavioral engagement with integration and the Experienced Integration Scale (EIS) to...

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

Scientific Reports April 7, 2022 Grant Jones, Jocelyn A. Ricard, Joshua Lipson et al. 56 citations

Abstract Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional treatments for the disorder. Classic psychedelics (psilocybin, peyote, mescaline, LSD) have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for OUD. The aim of this study was to assess...